bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
092-10-0004

Order Name:
NRAS/BRAF mutation-FFPE (Idylla)

 
Useful For:
Detection of 23 clinically significant mutations: 8 NRAS mutations in codons 12 and 13 (exon 2), 6 NRAS mutations in codons 59 and 61 (exon 3), 4 NRAS mutations in codons 117 and 146 (exon 4) and 5 BRAF mutations in codon 600 (exon 15) directly from formalin-fixed paraffin-embedded (FFPE) tissue sections.
 
Methodology:
Real-time PCR (PlexZyme™ and PlexPrime™ technology, Idylla™ System)
 
AliasesName:
NRAS/BRAF mutation
RAS/RAF
 
 
 
Test Code:
092-10-0004

Order Name:
NRAS/BRAF mutation-FFPE (Idylla)

 
Collection Specimen Or Container:
Tissue/ Formalin-fixed paraffin-embedded (FFPE) block
 
Specimen Testing Type:
Tissue, Formalin-fixed paraffin-embedded (FFPE) block,
2 x 10 µm FFPE tissue section, 25 – 300 mm² (≥ 10% Neoplastic cell content)
 
Sub Mission Container:
Tissue/Formalin-fixed paraffin-embedded (FFPE) block
 
Rejection Criteria:
Neoplastic cell content <10%
 
Specimen Stabillity:
Specimen Type Temperature Time
FFPE Tissue section Ambient temperature 1 month
 
 
 
Test Code:
092-10-0004

Order Name:
NRAS/BRAF mutation-FFPE (Idylla)

 
Method detail:
Real-time PCR (PlexZyme™ and PlexPrime™ technology, Idylla™ System)
 
Turnaround Time:
Received to Reported within 3 days
 
Performing Location:
Research and Development Tel. 14252
 
Specimen Retention Time:
1 month
 
 
 
Test Code:
092-10-0004

Order Name:
NRAS/BRAF mutation-FFPE (Idylla)

 
 
Clinical Information:
RAS genes still comprise the most frequently mutated oncogene family in human cancers being mutated e.g. in lung, colon, as well as pancreatic cancers. About 50% of all metastatic colorectal tumors harbor RAS mutations with the frequency of NRAS (exons 2, 3 & 4) and BRAF being 5% and 8%, respectively.
 
Clinical Reference:
  1. Cox AD et al. (2014) Nature Reviews Drug Discover 13, 828–851.
  2. Jean-Yves Douillard, M.D., Ph.D., Kelly S. Oliner, Ph.D., Salvatore Siena, M.D., et al. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med 2013;369:1023-34.
  3. http://us.biocartis.com/products-nras-braf (Retrieved 30 Jan 2019)